Update on PARP inhibitors for the treatment of ovarian cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) were initially approved for ovarian cancer, focusing on high-grade serous histology with BRCA mutations and homologous recombination deficiency (HRD).
• Early trials investigated PARPis in heavily pretreated, recurrent BRCA-mutated ovarian cancer.

Purpose of the Study:

• To review the evolving role and FDA approvals of PARPis in ovarian cancer.
• To discuss PARPi data in both newly diagnosed and recurrent settings.
• To analyze current PARPi combination therapies.

Main Methods:

• Review of clinical trial data and FDA approval history for PARPis in ovarian cancer.
• Analysis of efficacy and safety data in different treatment settings (newly diagnosed vs. recurrent).
• Examination of specific PARPis (olaparib, niraparib, rucaparib) and their indications.

Main Results:

• Concerns regarding overall survival led to withdrawal of most FDA approvals for PARPis in recurrent ovarian cancer.
• PARPis demonstrate significant progression-free survival benefits in the maintenance setting for newly diagnosed advanced ovarian cancer, particularly in BRCA-mutated patients.
• The incidence of secondary acute myeloid leukemia and myelodysplastic syndrome appears lower in the newly diagnosed setting compared to the recurrent setting.

Conclusions:

• The use of PARPis in ovarian cancer has shifted from recurrent disease to maintenance therapy in newly diagnosed advanced disease.
• Current FDA approvals reflect this shift, with PARPis approved for maintenance therapy and select recurrent settings.
• Combination therapies and ongoing research continue to shape the application of PARPis in ovarian cancer treatment.